Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trialFabio Efficace, Michael Lübbert, Sylvain Chantepie et al.|Blood|2024Cited by 18
10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SGFabio Efficace, Michael Luebbert, Gerwin Huls et al.|Blood|2022Cited by 3
Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Aged ≥60 Years Treated with a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study (NCT02172872)Adriano Venditti, Francesco Buccisano, Michal Kiciński et al.|Blood|2023Cited by 1